Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGTC-302
- Development stage
- Unknown
- Lead developer
- Syncona
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Subretinal
01
Overview
AGTC-302 is an investigational gene therapy product developed by Applied Genetic Technologies Corporation (AGTC) targeting inherited retinal diseases. AGTC-302 has been mentioned primarily as part of the AGTC pipeline but there is no confirmed public data or clinical trial identifying the specific target gene, construct, or patient population for this code name. AGTC is known for developing recombinant adeno-associated virus (AAV) based gene therapies for retinal diseases, particularly achromatopsia and X-linked retinitis pigmentosa, but AGTC-302 is not directly linked to any published clinical data or disease-specific trial in public sources as of October 2025. No details on mechanism of action, development status, or composition for AGTC-302 are currently available. The drug is presumed to follow AGTC's established modality of AAV-mediated gene delivery to retinal cells[2][3][4][5].
- Brand names
- AGTC-302AGTC302AGTC 302
- Other names
- AGTC-302AGTC302AGTC 302
02
Targets
CNGA3 (Cyclic nucleotide-gated channel subunit alpha 3)
Beyond the preview
Go deeper on AGTC-302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGTC-302.